Log in

NASDAQ:NERV - Minerva Neurosciences Stock Price, Forecast & News

$7.45
-0.10 (-1.32 %)
(As of 12/15/2019 03:34 PM ET)
Today's Range
$7.28
Now: $7.45
$7.60
50-Day Range
$4.08
MA: $5.56
$7.63
52-Week Range
$4.01
Now: $7.45
$8.83
Volume305,889 shs
Average Volume358,654 shs
Market Capitalization$290.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.32 per share

Profitability

Net Income$-50,170,000.00

Miscellaneous

Employees13
Market Cap$290.77 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.


Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences Inc (NASDAQ:NERV) posted its quarterly earnings data on Monday, November, 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.01. View Minerva Neurosciences' Earnings History.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Minerva Neurosciences.

What price target have analysts set for NERV?

3 Wall Street analysts have issued 12 month target prices for Minerva Neurosciences' stock. Their forecasts range from $17.00 to $26.00. On average, they expect Minerva Neurosciences' share price to reach $21.67 in the next year. This suggests a possible upside of 190.8% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences.

What is the consensus analysts' recommendation for Minerva Neurosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Minerva Neurosciences.

What are Wall Street analysts saying about Minerva Neurosciences stock?

Here are some recent quotes from research analysts about Minerva Neurosciences stock:
  • 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (10/29/2019)
  • 2. HC Wainwright analysts commented, "Valuation Our $22 price target for Minerva is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (5/31/2019)

Has Minerva Neurosciences been receiving favorable news coverage?

Media coverage about NERV stock has trended somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Minerva Neurosciences earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Minerva Neurosciences.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a increase in short interest in November. As of November 29th, there was short interest totalling 3,630,000 shares, an increase of 12.7% from the November 14th total of 3,220,000 shares. Based on an average daily trading volume, of 385,100 shares, the short-interest ratio is presently 9.4 days. Currently, 11.2% of the company's stock are sold short. View Minerva Neurosciences' Current Options Chain.

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:
  • Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)
  • Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)
  • Dr. Michael Davidson, Chief Medical Officer (Age 69)
  • Mr. Richard Russell, Pres (Age 55)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 44)

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.68%), State Street Corp (1.57%), Point72 Asset Management L.P. (0.42%), Alps Advisors Inc. (0.20%), Squarepoint Ops LLC (0.12%) and Barclays PLC (0.04%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View Institutional Ownership Trends for Minerva Neurosciences.

Which institutional investors are selling Minerva Neurosciences stock?

NERV stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Alps Advisors Inc. and Barclays PLC. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer and Venture Associates L Index III. View Insider Buying and Selling for Minerva Neurosciences.

Which institutional investors are buying Minerva Neurosciences stock?

NERV stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., State Street Corp, Metropolitan Life Insurance Co NY, Meeder Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and William F Doyle. View Insider Buying and Selling for Minerva Neurosciences.

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $7.45.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $290.77 million. The biopharmaceutical company earns $-50,170,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.View Additional Information About Minerva Neurosciences.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is http://www.minervaneurosciences.com/.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]


MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  529
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel